View the full list of medicines currently in development.
Each patient battling with a disease or managing a condition lives in the hope that tomorrow will bring a new medicine that delivers better health. America’s biopharmaceutical research companies share the same goal of developing new medicines that can prevent diseases, improve patients’ health, and save lives. Beyond each individual patient, new drugs can help society overall by reducing sick days and helping cut the cost of healthcare.
There are more than five million Americans living with Alzheimer’s today. For patients with Alzheimer’s and other dementia, America’s biopharmaceutical research companies are developing medicines to bring us closer to our goal of tackling and eventually conquering this debilitating disease.
View the full 2012 report on asthma medicines in development.
Today, more than
80 autoimmune diseases have been identified. Many more diseases are
thought to be autoimmune but have not been scientifically identified as
such, and others are considered to be autoimmune-related conditions.
View the PDF report listing the 800+ medicines in development to treat cancer.
America’s biopharmaceutical companies are developing new medicines to help meet the unique health care needs of children and adolescents. Considerable progress in the fight against diseases that impact children has been achieved in recent decades, with medicines playing a key role.
View the full 2015 report on medicines in development for leukemia and lymphoma.
Mental health conditions exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that 1 in 4 American adults—61.5 million—have been diagnosed with a mental health disorder.
Learn more about the specific medicines in development for neurological disorders and what phases they are in.
New Drug Approvals
In 2015, the Food and Drug Administration (FDA) approved a total of 57 new drugs and therapeutic biologics. Of those, a record 45 medicines were approved by the Center for Drug Evaluation and Research (CDER), while 12 biologics were approved by the Center for Biologics Evaluation and Research (CBER). The new medicines approved by the FDA in 2015 demonstrate the tireless work of America’s biopharmaceutical researchers and scientists to deliver on the promise of science.
With the population of Americans over 65 on the rise and life expectancy climbing, chronic diseases remain a principal threat to the health and productivity of older Americans, as well as to rising health care costs.
View the full 2014 report on medicines in development for older Americans.
Nearly 54 million adults in the United States have either osteoporosis or low bone density, according to the National Osteoporosis Foundation. Today, biopharmaceutical research companies are developing nine medicines for the treatment of osteoporosis.
View the full 2013 report on medicines in development for rare diseases.
America’s biopharmaceutical research companies currently are developing 277 medicines to help the more than 100 million Americans, one third of the U.S. population, that suffer from at least one skin disease.